Mary D. Chamberlin

Also affiliated with Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth–Hitchcock Medical Center, Dartmouth Psychiatric Research Center, Dartmouth Cancer Center

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 14 papers. Top paper: “A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)”.

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2182

N/A

3.8DataRank · unranked

125 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0112

N/A

0.523DataRank · unranked

8 citations

Peter A. Kaufman, Karthik V. Giridhar, Jonathan D. Marotti, Mary D. Chamberlin, Bradley A. Arrick +7 more

Study protocol for a multisite randomised controlled trial of a rehabilitation intervention to reduce participation restrictions among female breast cancer survivors

BMJ Open(2020)10.1136/bmjopen-2020-036864

N/A

0.516DataRank · unranked

13 citations

Mark T. Hegel, Marie Bakitas, Martha L. Bruce, Andrés Azuero, Maria Pisu +17 more

Surgeon and medical oncologist peer network effects on the uptake of the 21‐gene breast cancer recurrence score assay

Cancer Medicine(2021)10.1002/cam4.3720

N/A

0.360DataRank · unranked

10 citations

Andrew Schaefer, Mary D. Chamberlin, Tracy Onega, A. James O’Malley, Erika L. Moen +1 more

Exercise That Feels as Good as Possible: Acceptability of an Affect‐Based Exercise Prescription Among Stage 0–III Breast Cancer Survivors

Psycho-Oncology(2025)10.1002/pon.70225

N/A

0.104DataRank · unranked

1 citations

Carly A. Bobak, Kali J. Morrissette, Ryan C. Thompson, Kathleen Doyle Lyons, Grace M. Wallace +6 more

Use of the ORBIT model to refine and test a novel approach to exercise promotion for breast cancer survivors based on affect regulation.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps12153

N/A

0DataRank · unranked

0 citations

Kali Morrissette, Kathleen Doyle Lyons, Jennifer A. Emond, Sarah K. Walsh, Grace M Crummer +5 more

Near-Infrared Spectral Tomography for Predicting Residual Cancer Burden during Early-Stage Neoadjuvant Chemotherapy for Breast Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1593

N/A

0DataRank · unranked

5 citations

Kristen E. Muller, Mary D. Chamberlin, Jiang Gui, Peter A. Kaufman, Gary N. Schwartz +5 more

Kynurenine‐Induced Aryl Hydrocarbon Receptor Signaling in Mice Causes Body Mass Gain, Liver Steatosis, and Hyperglycemia

Obesity(2021)10.1002/oby.23065

N/A

0DataRank · unranked

51 citations

Benjamin Moyer, Carol S. Ringelberg, Owen M. Wilkins, Darcy B. Pooler, Dylan B. Ness +6 more

Data from A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

(2023)10.1158/1078-0432.c.6530837

N/A

0DataRank · unranked

0 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylation

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.09.26.615177

N/A

0DataRank · unranked

3 citations

Mary D. Chamberlin, Huijuan Yang, Jonathan D. Marotti, Alyssa M. Roberts, Melissa M. Carmichael +11 more

Prevalence of Human Papillomavirus‐Associated Head and Neck Cancer in Rwanda: A 10‐Year Review

Cancer Medicine(2024)10.1002/cam4.70423

N/A

0DataRank · unranked

0 citations

Lydia Businge, Wilma Hopman, Gad Murenzi, Aline Uwimbabazi, Vincent Kwizera +10 more

Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy–Tolerant Persister Cells in ER+ Breast Cancer

Cancer Research(2025)10.1158/0008-5472.can-24-1204

N/A

0DataRank · unranked

17 citations

Mary D. Chamberlin, Huijuan Yang, Jonathan D. Marotti, Patricia C. Muskus, Alyssa M. Roberts +12 more

Data from A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

10.1158/1078-0432.c.6530837.v1

N/A

0DataRank · unranked

0 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

Prioritizing Measures That Matter Within a Person-Centered Oncology Learning Health System

JNCI Cancer Spectrum(2022)10.1093/jncics/pkac037

N/A

0DataRank · unranked

6 citations

Alice Kennedy, Kathryn B Kirkland, Konstantin H. Dragnev, Steven D. Leach, Madge E. Buus‐Frank +81 more